Sun Pharma to stay disciplined on M&A, says Dilip Shanghvi

Sun Pharma plans a careful acquisition strategy. The company prioritizes organic growth to remain an attractive investment. Chairman Dilip Shanghvi highlighted a focus on innovative medicines in the US. Smaller acquisitions are being considered for emerging markets. The firm is also evaluating the biosimilar sector. This approach aims to strengthen long-term capabilities.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/AgdF51Y
via IFTTT